| | |
All factors assessed by fDM
|
|---|
| | |
VD(%)
|
VI(%)
|
VNC(%)
|
Min ADC (10-5mm2/sec)
|
Max ADC (10-5mm2/sec)
|
RECIST (cm)
|
Volume reduction rate of enhanced lesion (%)
|
|---|
| | |
> 12.4
|
≤ 12.4
|
< 3.6
|
≥ 3.6
|
< 74.6
|
≥ 74.6
|
< 70
|
≥ 70
|
< 368
|
≥ 368
|
< 40.3
|
≥ 40.3
|
< −21.1
|
≥ −21.1
|
|
Median time (M)
|
19.3
|
10.3
|
11.2
|
12.1
|
15.3
|
11
|
14.3
|
9.1
|
11.2
|
12.1
|
14.2
|
10.8
|
15.1
|
9.7
|
|
95% CI
|
13.4-
|
7.8-
|
7.2-
|
7.8-
|
6.9-
|
7.8-
|
7.8-
|
7.2-
|
7.2-
|
6.9-
|
7.8-
|
7.2-
|
11.2-
|
7.2-
|
|
(M)
|
45.9**
|
13.4**
|
45.9
|
15.3
|
45.9
|
15.1
|
22.7**
|
10.8**
|
23.2
|
15.1
|
45.9
|
15.1
|
45.9
|
15.3
|
|
p value
|
log-rank
|
0.022*
|
0.521
|
0.128
|
0.011*
|
0.176
|
0.118
|
0.143
|
|
wilcoxon
|
0.033*
|
0.834
|
0.35
|
0.045*
|
0.413
|
0.223
|
0.083
|
- *VD and Min ADC at 2 days after BNCT showed a significant difference using log-rank test and wilcoxon test. **However, Min ADC showed over-lap in 95% CI. On the other hand, VD showed no over-lap in 95% CI.
